Literature DB >> 6840168

Sustained serum theophylline concentrations during chronic twice daily administration of a slow release preparation.

S H Jackson, J M Wright.   

Abstract

Theophylline concentrations were measured in a clinical setting in 15 patients given a slow release theophylline preparation (Theo-Dur) every 12 h for reversible obstructive airways disease. Doses of 300-600 mg (464 +/- 134), 12 hourly, resulted in mean serum concentrations which increased from 11.2 +/- 2.9 micrograms/ml at 0 h to a peak of 15.5 +/- 4.6 micrograms/ml at 6 h and decreased again to 10.4 +/- 2.9 micrograms/ml at 12 h. The mean percentage fluctuation of serum concentrations (maximum minus minimum expressed as a % of the maximum) was 38.6 +/- 10.1%, range 20.3% to 54.9%. There was a significant positive correlation between % fluctuation and theophylline steady-state clearance determinations. Excluding a single heavy smoker, theophylline clearance also showed a significant inverse relationship with age. These data suggest that when this slow release preparation is given 12 hourly, satisfactorily sustained serum theophylline concentrations will be achieved in most adults.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840168     DOI: 10.1007/bf00613818

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children.

Authors:  G Levy; R Koysooko
Journal:  J Pediatr       Date:  1975-05       Impact factor: 4.406

Review 2.  Monitoring serum theophylline levels.

Authors:  L Hendeles; M Weinberger; G Johnson
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease.

Authors:  J Dasta; J M Mirtallo; M Altman
Journal:  Am J Hosp Pharm       Date:  1979-05

4.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

5.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

6.  Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics.

Authors:  P H Scott; E Tabachnik; S MacLeod; J Correia; C Newth; H Levison
Journal:  J Pediatr       Date:  1981-09       Impact factor: 4.406

7.  Temporal variations in trough serum theophylline concentrations at steady state.

Authors:  L J Lesko; D Brousseau; A T Canada; G Eastwood
Journal:  J Pharm Sci       Date:  1980-03       Impact factor: 3.534

8.  Theophylline bioavailability following oral administration of six sustained-release preparations.

Authors:  D L Spangler; D D Kalof; F L Bloom; H J Wittig
Journal:  Ann Allergy       Date:  1978-01

9.  Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.

Authors:  C Richer; M Mathieu; H Bah; C Thuillez; P Duroux; J F Giudicelli
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

10.  Cimetidine impairs the elimination of theophylline and antipyrine.

Authors:  R K Roberts; J Grice; L Wood; V Petroff; C McGuffie
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  5 in total

1.  The relationship between clearance of theophylline and age within the adult age range.

Authors:  S H Jackson; J K Wiffen; A Johnston; C A Peverel-Cooper
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Theophylline pharmacokinetics following single and repeated administration of slow-release capsules.

Authors:  J Torrent; I Izquierdo; M J Barbanoj; R Obach; M Nomen; F Jane
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

3.  Methods of comparing pharmacokinetics of slow release preparations: a comparison of "Theo-Dur" and "Phyllocontin" in patients with asthma.

Authors:  S H Jackson; K Shah; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans.

Authors:  I Raz; M Bialer; K Salame; H Bar-On
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Prescribing habits for theophylline preparations.

Authors:  J K Wiffen; S H Jackson
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.